Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 11151 - 11175 of 11782 in total
Cefilavancin is a covalently-linked glycopeptide-cephalosporin (beta-lactam) heterodimer antibiotic that exhibits substantially greater activity than its component parts against Gram-positive bacteria.
Investigational
Matched Description: … Cefilavancin is a covalently-linked glycopeptide-cephalosporin (beta-lactam) heterodimer antibiotic that …
A conjugate of an anti-glycoprotein non-metastatic melanoma protein B mAb and monomethyl auristatin E for the treatment of melanoma and breast cancer.
Investigational
Matched Description: … A conjugate of an anti-glycoprotein non-metastatic melanoma protein B mAb and monomethyl auristatin E …
MLN2222 is a novel, proprietary recombinant protein that blocks both the C3 and C5 convertases, which are essential components of the complement activation pathway.
Investigational
Matched Description: … MLN2222 is a novel, proprietary recombinant protein that blocks both the C3 and C5 convertases, which …
Rivoglitazone (INN) is a thiazolidinedione undergoing research for use in the treatment of type 2 diabetes. It is being developed by Daiichi Sankyo Co.
Experimental
Investigational
Matched Description: … Rivoglitazone (INN) is a thiazolidinedione undergoing research for use in the treatment of type 2 diabetes …
A selective androgen receptor modulator with minimal prostate hypertrophic activity, enhances lean body mass in male rats and stimulates sexual behavior in female rats.
Experimental
Matched Description: … A selective androgen receptor modulator with minimal prostate hypertrophic activity, enhances lean body …
An element with atomic symbol Cd, atomic number 48, and atomic weight 112.41. It is a metal and ingestion will lead to CADMIUM POISONING.
Experimental
Matched Description: … It is a metal and ingestion will lead to CADMIUM POISONING. …
Balovaptan is under investigation in clinical trial NCT01793441 (A Study of RG7314 to Investigate Efficacy and Safety in Individuals With Autism Spectrum Disorders (ASD)).
Investigational
Matched Description: … Balovaptan is under investigation in clinical trial NCT01793441 (A Study of RG7314 to Investigate Efficacy …
TP-271 is under investigation in clinical trial NCT02724085 (A Phase 1 Study to Assess the Safety, Tolerability and PK of IV TP-271).
Investigational
Matched Description: … TP-271 is under investigation in clinical trial NCT02724085 (A Phase 1 Study to Assess the Safety, Tolerability …
Edratide is under investigation in clinical trial NCT00203151 (A Study to Evaluate the Tolerability, Safety and Effectiveness of Edratide in the Treatment of Lupus).
Investigational
Matched Description: … Edratide is under investigation in clinical trial NCT00203151 (A Study to Evaluate the Tolerability, …
Ravoxertinib is under investigation in clinical trial NCT01875705 (A Dose-Escalation Study of GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors).
Investigational
Matched Description: … Ravoxertinib is under investigation in clinical trial NCT01875705 (A Dose-Escalation Study of GDC-0994 …
Ridinilazole is under investigation in clinical trial NCT02092935 (A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)).
Investigational
Matched Description: … Ridinilazole is under investigation in clinical trial NCT02092935 (A Study of SMT19969 Compared With …
NDX-3315 is an investigational radiopharmaceutical agent for the diagnosis, treatment monitoring, and management of eosinophilic esophagitis. It is a technetium-99m radiolabeled heparin.
Investigational
Matched Description: … It is a technetium-99m radiolabeled [heparin]. …
GPI 1485 is a product candidate that belongs to a class of small molecule compounds called neuroimmunophilin ligands. In preclinical experiments, neuroimmunophilin ligands have been shown to repair and regenerate damaged nerves without affecting normal, healthy nerves. GPI 1485 is being studied in phase 2 clinical trials for the treatment...
Investigational
Matched Description: … GPI 1485 is a product candidate that belongs to a class of small molecule compounds called neuroimmunophilin …
VXA-CoV2-1 is a non-replicating adenoviral vector-based oral tableted vaccine candidate that expresses a SARS-CoV-2 antigen and dsRNA adjuvant . This oral vaccine aims to induce immunogenicity through induction of potent serum neutralizing antibodies to the SARS-CoV-2 spike protein, induction of mucosal immune responses, and induction of T-cell responses to both...
Investigational
Matched Description: … a SARS-CoV-2 antigen and dsRNA adjuvant[L30493]. ... VXA-CoV2-1 is a non-replicating adenoviral vector-based oral tableted vaccine candidate that expresses …
Gam-COVID-Vac was created by Gamaleya Research Institute of Epidemiology and MIcrobiology in Russia. The vaccine candidate is a heterologous COVID-19 vaccine containing two components, recombinant adenovirus type 26 (rAd26) vector and recombinant adenovirus type 5 (rAd5) vector which both carry the SARS-CoV-2 spike glycoprotein. The vaccine is offered in both...
Investigational
Matched Description: … The vaccine candidate is a heterologous COVID-19 vaccine containing two components, recombinant adenovirus ... The vaccine is offered in both a frozen (Gam-COVID-Vac) and freeze-dried formulation (lyophilizate; Gam-COVID-Vac ... Preliminary results suggested that all participants developed antibodies to the SARS-CoV-2 glycoproteins with a
XAV-19 is an intravenous antibody-based treatment targeted towards SARS-CoV-2 and other coronaviruses[L16553,L16558]. The therapy concept is based on COVID-19 convalescent plasma. However, rather than using human plasma, XAV-19 is a heterologous swine glyco-humanized polyclonal antibody that targets the spike protein of SARS-CoV-2[L16553,L16558]. The therapy offers three beneficial effects: the ability...
Investigational
Matched Description: … However, rather than using human plasma, XAV-19 is a heterologous swine glyco-humanized polyclonal antibody ... As of July, 2020, the company is conducting a Phase 2 randomized clinical trial to define dosing safety ... Xenothera has partnered with LFB, a pharmaceutical company, to develop XAV-19, and with Nantes University …
Emrusolmin restores hippocampal synaptic and transcriptional plasticity as well as spatial memory in a mouse model for Alzheimer's disease, when given orally before or after the onset of pathology.
Experimental
Matched Description: … Emrusolmin restores hippocampal synaptic and transcriptional plasticity as well as spatial memory in a
Rovafovir etalafenamide is under investigation in clinical trial NCT03472326 (Efficacy of GS-9131 Functional Monotherapy in HIV-1-Infected Adults Failing a Nucleos(t)Ide Reverse Transcriptase Inhibitor-Containing Regimen).
Investigational
Matched Description: … clinical trial NCT03472326 (Efficacy of GS-9131 Functional Monotherapy in HIV-1-Infected Adults Failing a
Brimapitide is under investigation in clinical trial NCT01570205 (Safety, Tolerability and PK of a Single iv Infusion of 10, 40, and 80 µg/kg XG-102 Administered to Healthy Volunteers).
Investigational
Matched Description: … Brimapitide is under investigation in clinical trial NCT01570205 (Safety, Tolerability and PK of a Single …
TERN-101 is under investigation in clinical trial NCT04328077 (LIFT Study: A Safety, Tolerability, Efficacy, and Pharmacokinetics Study of TERN-101 in Subjects With Non-cirrhotic Non-alcoholic Steatohepatitis (NASH)).
Investigational
Matched Description: … TERN-101 is under investigation in clinical trial NCT04328077 (LIFT Study: A Safety, Tolerability, Efficacy …
ORP-101 is under investigation in clinical trial NCT04129619 (A Comparison of the Effects of ORP-101 Versus Placebo in Adult Patients With Irritable Bowel Syndrome With Diarrhea (IBS-D)).
Investigational
Matched Description: … ORP-101 is under investigation in clinical trial NCT04129619 (A Comparison of the Effects of ORP-101 …
Displaying drugs 11151 - 11175 of 11782 in total